News
ALNY
301.98
-1.01%
-3.08
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny
Simply Wall St · 1d ago
Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach
Seeking Alpha · 1d ago
Alnylam Shareholders Reaffirm Board, Pay Practices and Auditor
TipRanks · 2d ago
Alnylam shareholders back executive pay in advisory vote at annual meeting
PUBT · 2d ago
Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Insulet (PODD)
TipRanks · 3d ago
Weekly Report: what happened at ALNY last week (0518-0522)?
Weekly Report · 5d ago
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake
Simply Wall St · 05/23 14:28
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
Seeking Alpha · 05/21 21:40
J.P. Morgan Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
TipRanks · 05/20 09:16
U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv
Reuters · 05/20 07:07
Ionis, Alnylam, BioMarin up as Citi starts at Buy on catalyst and growth outlook
Seeking Alpha · 05/19 18:01
IBB, GILD, REGN, ALNY: ETF Outflow Alert
NASDAQ · 05/19 14:50
Alnylam Pharmaceuticals Initiated at Buy by Citigroup
Dow Jones · 05/19 14:43
Alnylam Pharmaceuticals Price Target Announced at $380.00/Share by Citigroup
Dow Jones · 05/19 14:43
Citigroup Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces Price Target of $380
Benzinga · 05/19 14:33
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
TipRanks · 05/19 13:35
Alnylam publishes 2025 corporate responsibility report
PUBT · 05/19 12:30
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors
Simply Wall St · 05/19 10:33
ALNYLAM PHARMACEUTICALS INC <ALNY.O>: CITIGROUP INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $380
Reuters · 05/19 10:30
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Reuters · 05/19 07:56
More
Webull provides a variety of real-time ALNY stock news. You can receive the latest news about Alnylam Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.